Commerce Dashboard

Sun Pharmaceuticals

Go Back

Sun Pharmaceuticals

  • World’s fifth largest specialty generic pharmaceutical company
  • Serves over 150 markets across the world
  • More than 2,000 marketed products
  • More than 40 manufacturing sites
  • In FY20, company’s total income reached Rs 33,473.48 crore (US$ 4.75 billion)

Sun Pharmaceuticals is the largest pharmaceutical company from India and the fifth largest specialty generic company in the world. It has capabilities across dosage forms like injectables, sprays, ointments, creams, liquids, tablets, and capsules. Its businesses include producing generics, branded generics, speciality, over the counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and intermediates in the full range of dosage forms. It also produces specialty APIs. In FY19, US formulations contributed the most to company’s sales with 37%, followed by India branded formulations at 26%.

Company Website:

Sun Pharma – Reaching People. Touching Lives.


In June 2021, Sun Pharmaceuticals acquired the patent license for Dapagliflozin from AstraZeneca. The company will distribute and promote the drug under the brand name ‘Oxra’.
In May 2021, the company entered a royalty-free, non-exclusive licensing agreement with Eli Lilly and Company to expand access to the COVID-19 drug, Baricitinib. The company will manufacture and distribute the drug in India. March 2021, Sun Pharmaceuticals acquired a 12.5% stake in Australia-based WRS Bioproducts for US$ 1.5 million.
In February 2021, the company launched a website for its long-term care portfolio in the US, highlighting the efficacy and safety profile for each product.
In February 2021, it introduced Brivaracetam, an anti-epileptic drug, in multiple dosage forms, a day after the patent expiry. This drug was developed by UCB, a Belgian-based firm.

2020 Sun Pharma announced five-year sustained efficacy and safety results for ILUMYA in patients with moderate-to-severe plaque psoriasis
2019 Sun Pharma and AstraZeneca entered into a license agreement for novel oncology products in China
Sun Pharma’s arm, Sun Pharmaceutical Industries, acquired its remaining 3.04% stake in PJSC Biosintez, Russia
Sun Pharma and China Medical System Holdings entered into licensing agreement for generic products in Mainland China
2018 Sun Pharma to acquire Pola Pharma in Japan
2018 Sales of Rs 27,956 crore (US$ 4 billion) in FY18; Announced acquisition of US-based speciality pharmaceutical company Avenue Therapeutics for Rs 1502.635 crore (US$ 215 million)
2017 Agreement signed with National Institute of Virology, India to fight Zika, Chikungunya and Dengue
2013 Became world’s fifth largest specialty generic pharmaceutical company with acquisition of Ranbaxy
2000 Acquired Pradeep Drug Company
1997 First international acquisition with Caraco Pharmaceutical Laboratories, USA
1996 Sales network expanded across 24 countries
1994 Launched initial public offer (IPO)
1989 Introduced gastroenterology products in India
1983 Established with a portfolio of five psychiatry products


India ranks 3rd worldwide for pharmaceutical production by volume and 14th by value. The country has an established domestic pharmaceutical industry, with a strong network of 3,000 drug companies and ~10,500 manufacturing units.